News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pacira Pharmaceuticals, Inc. Pain Drug Fails Late-Stage Trial



8/2/2013 7:36:33 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Pacira Pharmaceuticals, Inc. (PCRX: Quote) Thursday said results from a late-stage study with Exparel in intercostal nerve block did not meet the primary endpoint of pain reduction. The stock plunged 12 percent in the extended trade. The company's second pivotal, Phase 3 clinical trial assessed the safety and efficacy of Exparel (bupivacaine liposome injectable suspension) in intercostal nerve block for a surgical procedure known as posterolateral thoracotomy.

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters
Read at RTT News
Read at BusinessWeek
Read at Wall Street Journal


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES